Rates of next-generation sequencing (NGS) more than doubled once a nurse navigation program was implemented.
Implementing a nurse navigator program can increase the likelihood that patients with epithelial ovarian cancer receive timely molecular tumor testing, according to a new report.
The study, published in Cancers, also showed that the program led to a higher rate of actionable mutation detection.
Its authors noted that the National Comprehensive Cancer Network recommends germline and somatic tumor testing for all patients with epithelial ovarian cancer, since the identification of certain mutations can help guide treatment decisions. Despite those recommendations, only about 30% of patients undergo genetic testing and only 22.9% of patients undergo molecular testing.
One potential solution to increase testing rates is the implementation of a nurse navigator program, the authors said. Previous research shows that inserting navigators into the treatment process can lead to significant increases in the rate of molecular tumor testing. They therefore implemented a nurse navigator program at the University of Kentucky’s Markey Cancer Center beginning in September 2021. This new study documents the impact of the program.
The new program called for a nurse navigator to conduct an initial education session with gynecological surgeons to ensure they understood the guidelines and the treatment implications for patients with mutations. Thereafter, the nurse navigator was responsible for interacting with gynecologic oncology tumor boards, recommending and ordering next-generation sequencing (NGS) as appropriate, facilitating NGS testing and reporting, and ensuring results were communicated to necessary parties.
The authors of the study compared the outcomes of 34 patients with epithelial ovarian cancer who were treated at the cancer center before the nurse navigator program with the outcomes of 44 patients who were treated following the program’s implementation.
Before the nurse navigator program, 35.29% of patients were given NGS testing, but after implementation, the rate rose to 77.27%. Before the program, the most common reason patients were not given NGS testing was because targeted panel testing had been ordered. However, after the program was implemented, the most common reason was the cancer’s characteristics, the authors said. They said supplemental training was provided after it was discovered that NGS was inappropriately skipped despite the nurse navigator program.
The nurse navigator also significantly sped up the timetable required for testing. Prior to the program, the total turnaround time for testing was 145.2 days; after nurse navigators were put in charge of coordinating testing, the turnaround time shrunk to an average of 42.8 days.
“On discussion with the nurse navigator, they think their nursing background helped them understand who was a candidate for testing, troubleshoot, and feel confident in recommending testing to the physician if the physician did not recommend testing when indicated,” the authors wrote.
The program ultimately led to a higher rate of actionable mutations being found, the authors said. Two-thirds (67.6%) of patients with recurrent cancers were found to have actionable mutations in the postimplementation period compared with 20.8% before the nurse navigator program. In the frontline setting, there was also a higher rate of actionable mutations, although the difference was less pronounced. The authors said the increase in mutation identification was due to the higher use of NGS, since many of the actionable mutations identified would not have been found using targeted panel testing.
The investigators said their findings confirm that nurse navigators can play an important role in ensuring guidelines are followed and ultimately in improving patient care.
Reference
Rives TA, Pavlik H, Li N, et al. Implementation of nurse navigation improves rate of molecular tumor testing for ovarian cancer in a gynecologic oncology practice. Cancers (Basel). Published online June 15, 2023. doi:10.3390/cancers15123192
Bringing Connectivity to the Specialty Pharmacy Workflow
May 2nd 2024In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized the need to simplify the prescribing workflow for specialty medication through proactive messaging, automation, and interoperability.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
Forging a Patient-Centric Path to Revolutionize and Redefine Value-Based Care
April 30th 2024Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.
Read More
Bringing Connectivity to the Specialty Pharmacy Workflow
May 2nd 2024In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized the need to simplify the prescribing workflow for specialty medication through proactive messaging, automation, and interoperability.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
Forging a Patient-Centric Path to Revolutionize and Redefine Value-Based Care
April 30th 2024Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.
Read More
2 Commerce Drive
Cranbury, NJ 08512